Active substance
Results for the substance pneumococcal polysaccharide conjugate vaccine 21-valent
1 result
About this active substance
The 21-valent pneumococcal polysaccharide conjugate vaccine is designed to protect against infections caused by 21 different serotypes of the Streptococcus pneumoniae bacterium. This vaccine is used to prevent pneumococcal diseases such as pneumonia, meningitis, sepsis, and otitis media, particularly in high-risk groups such as young children, the elderly, and individuals with chronic conditions or immunosuppression.
The vaccine is conjugated, meaning that the capsular polysaccharides of the bacterium are linked to a carrier protein, which enhances the immune response, especially in children under 2 years old, who have an underdeveloped immune system.
It is administered via intramuscular injection according to a vaccination schedule established by public health authorities. The vaccine is well-tolerated, but mild side effects such as pain at the injection site, fever, or fatigue may occur. Severe reactions are rare.
It is important for patients to follow the recommended vaccination schedule to ensure optimal protection against pneumococcal diseases.
The vaccine is conjugated, meaning that the capsular polysaccharides of the bacterium are linked to a carrier protein, which enhances the immune response, especially in children under 2 years old, who have an underdeveloped immune system.
It is administered via intramuscular injection according to a vaccination schedule established by public health authorities. The vaccine is well-tolerated, but mild side effects such as pain at the injection site, fever, or fatigue may occur. Severe reactions are rare.
It is important for patients to follow the recommended vaccination schedule to ensure optimal protection against pneumococcal diseases.